Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazine SCHEMBL28746322 | 1.00 | MAPK1 (0.46) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL5159688 | 0.89 | SLC1A3 (0.55) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL2295611 | 0.89 | SLC1A3 (0.55) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Phenazine SCHEMBL28881744 | 0.83 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1ALDH1A1KDM4E | |
| Phenazine SCHEMBL29879113 | 0.83 | KDM4E (0.58) | MAPK1CYP2D6ALDH1A1KDM4ESMN1; SMN2 | |
| Phenazine SCHEMBL29609188 | 0.83 | KDM4E (0.58) | MAPK1CYP2D6ALDH1A1KDM4ESMN1; SMN2 | |
| Threonine SCHEMBL18075540 | 0.82 | SLC1A3 (0.54) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL3254315 | 0.78 | SLC1A3 (0.51) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL723059 | 0.78 | SLC1A3 (0.51) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL3725637 | 0.78 | SLC1A3 (0.51) | MAPK1CYP2D6SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114679906-A | Methods of administering specific VMAT2 inhibitors to patients with severe renal impairment | 纽罗克里生物科学有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-112867491-A | Methods of administering certain VMAT2 inhibitors | 纽罗克里生物科学有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-111836543-A | Methods of administering certain VMAT2 inhibitors | 纽罗克里生物科学有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-111655034-A | Methods of administering certain VMAT2 inhibitors | 纽罗克里生物科学有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-110769826-A | Methods of administering certain VMAT2 inhibitors | 纽罗克里生物科学有限公司 | 2020-02-07 | — | — | CN | disclosed |